DOCS Earnings

DOCS reported its earnings on 2026-02-05, showcasing a revenue of 185.05M against an estimate of 181.03M, resulting in a 2.22% surprise. The EPS was 0.46, surpassing the expected 0.45 by 2.22%. The stock experienced a -16.78% price change on the earnings day and a -22.09% change over the next five days, reflecting market reactions to the results.

Following DOCS's earnings announcement on 2026-02-05, the stock price moved by -16.78% on the day of the release. Over the subsequent five days, it saw a -22.09% change. Historically, DOCS's stock price tends to shift by an average of 4.83% in the 10 days leading up to earnings and 2.31% in the 10 days following, providing insight into potential market.

For 2026/Q4, analysts estimate DOCS's annual revenue to reach 150.34M, while the EPS is projected at 0.32. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between DOCS's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2026 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, DOCS's stock price typically moves by 4.83% in the 10 days before its earnings and 2.31% in the 10 days after. For the upcoming 2026/Q4 earnings, analysts expect an EPS of 0.32 and revenue of 150.34M.

The earnings call summary indicates a generally positive outlook. The financial performance shows growth in revenue and EBITDA margins, driven by a strong pharma business and AI investments. However, there is some uncertainty in market conditions affecting client budgets. The Q&A section reveals management's confidence in product differentiation and market expansion strategies, despite competitive pressures. The company's strategic investments in AI and marketing, along with optimistic revenue and EBITDA guidance, suggest a positive sentiment. Despite some uncertainties, the overall tone is optimistic, leading to a positive prediction for stock price movement.